 |
|
|
| |
Evaluation of Factors Associated With Differences in ALT Normalization
Between Virally Suppressed TAF- and TDF-Treated CHB Patients
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
Harry L. Janssen,1 Shalimar,2 Chi-Yi Chen,3 Owen Tak Yin Tsang,4 Jenny C. Yang,5 Hongyuan Wang,5 Anuj Gaggar,5 John F. Flaherty,5 Mani Subramanian,5 Huy N. Trinh,6 Florin A. Caruntu,7 Maria Buti,8 Scott Fung1
1Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; 2All India Institute of Medical Sciences, New Delhi, India; 3Chia-Yi Christian Hospital, Chiayi City, Taiwan; 4Princess Margaret Hospital, Hong Kong;
5Gilead Sciences, Inc., Foster City, CA; 6Silicon Valley Research Institute, San Jose, CA; 7National Institute for Infectious Diseases "Prof. Dr. Matei Bals," Bucharest, Romania; 8Hospital Vall d'Hebron, Barcelona, Spain
References
1. Agarwal K, et al. EASL 2017, abstr 153; 2. Brunetto M, et al. EASL 2017, abstr PS-042;
3. Chan HL, et al. EASL 2017, abstr PS-041; 4. Fung S, et al.
AASLD 2016, abstr 1852; 5. Terrault NA, et al. Hepatology 2016;63:261-83.
|
| |
|
|
|
|
|
